Pyrazolyl Ureas as Kinase Inhibitors
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/GB2015/050401, filed Feb 13, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,884,845 | Pyrazolyl Ureas as Kinase Inhibitors In force · High confidence | Respivert Limited | In force | High confidence | ||
| US 10,294,216 | Pyrazolyl Ureas as Kinase Inhibitors In force · Medium confidence | Respivert Limited | In force | Medium confidence | ||
| US 11,142,515 | Pyrazolyl-Ureas as Kinase Inhibitors In force · Medium confidence | Respivert Limited | In force | Medium confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.